Dermata shareholders approve reverse stock split (1:5-1:30) and equity plan expansion

Dermata Therapeutics, Inc.

Stockholders approved reverse stock split at ratio from 1:5 to 1:30, exact ratio to be set by Board.
Equity plan amended to increase share reserve from 629,069 to 1,198,951 and raise annual evergreen to 5%.
Three Class III directors elected: Proehl, Wierenga, and Scott.
Ratified Moss Adams LLP as auditor for FY2024.
Adjournment proposal also approved.

item 5.02 item 5.07 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Dermata Therapeutics, Inc. shareholders approved Election of three Class III directors.

Proposal: director election
Outcome: passed

Exact text from the filing

The matters voted on at the Annual Meeting were: (1) the election of three Class III directors

View on SEC.gov

303 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Dermata Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-24-005715

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.